

## SESQUITERPENOID METABOLITES FROM *STEREUM COMPLICATUM*

GRAHAM MELLOWS, PETER G. MANTLE and TIMOTHY C. FELINE

Department of Biochemistry

and

DAVID J. WILLIAMS

Chemical Crystallography Laboratory, Imperial College, London SW7 2AY

(Received 30 April 1973. Accepted 5 June 1973)

**Key Word Index**—*Stereum complicatum*: Basidiomycete; complicatic acid; hirsutic acid *C*; sesquiterpenes; antibiotics; biosynthesis.

**Abstract**—A new sesquiterpene antibiotic, complicatic acid, isolated from cultures of *Stereum complicatum* (Fr.) Fr. has been shown to be dehydrohirsutic acid *C*. Hirsutic acid *C* was also isolated from the same fungus. [2-<sup>14</sup>C]-MVA was incorporated into both metabolites and complicatic acid has been shown to be formed from hirsutic acid *C* both *in vivo* and *in vitro*.

### INTRODUCTION

IN A PREVIOUS paper<sup>1</sup> we reported that, in submerged fermentations where the pH value was controlled, the American timber decomposing Basidiomycete, *Stereum complicatum* (Fr.) Fr., produced an oily, acidic, antimicrobial metabolite (*ca.* 200 mg/l. after 12 days) to which we ascribed the name complicatic acid (substance *B*). We have since shown<sup>2</sup> that a fermentation in which the pH value was allowed to fall produced, in addition to small amounts of *B*, a second acidic substance, *A* (500 mg/l.). We now report on the identity and biosynthesis of *A* and *B*.

### RESULTS AND DISCUSSION


The m.p.,  $[\alpha]_D$  and spectral data of metabolite *A* and its *p*-bromophenacyl ester were in excellent agreement with literature values for hirsutic acid *C* (I, R=H) and its ester (I, R = CH<sub>2</sub>COC<sub>6</sub>H<sub>4</sub> *p*-Br).<sup>3</sup> Unit cell and intensity data for the *p*-bromophenacyl ester of *A* agreed well with those obtained in the X-ray study of hirsutic acid *C*<sup>4</sup>, but, by minimising radiation damage, a higher resolution was achieved. The resulting structure ( $R = 0.075$ ) revealed an intermolecular hydrogen bond (2.87(2)Å) between the 5β-hydroxyl and the epoxide oxygen, which had been ruled out in the earlier study.\*

The IR ( $\nu_{\max}$  1700, 1645 and 900 cm<sup>-1</sup>) and UV ( $\lambda_{\max}$  234 nm ( $\epsilon$ 4500)) spectra of metabolite *B*, C<sub>15</sub>H<sub>18</sub>O<sub>4</sub> (high resolution MS), indicated the presence of an exomethylene cyclopentanone ( $\lambda_{\text{calc}}$ <sup>5</sup> 230 nm). The NMR spectrum indicated that *A* and *B* were structurally related and showed the loss of H<sub>c</sub>. H<sub>a</sub>, H<sub>b</sub> and H<sub>d</sub> appeared as singlets lacking the long-range

\* Full details of the refined structure will be published elsewhere.

<sup>1</sup> MANTLE, P. G. and MELLOWS, G. (1972) *J. Gen. Microbiol.* **73**, xxii.

couplings of  $H_a$ ,  $H_b$  to  $H_c$  (ca. 2–3 Hz) as observed in *A*. Structure II was therefore suggested for *B*. The relationship of *B* to *A* was proved by reduction of *B* with  $\text{NaBH}_4$  in EtOH which gave *A* and by oxidation of *A* with  $\text{MnO}_2$  in  $\text{CHCl}_3$  which afforded *B*.



Hirsutic acid *C* was first isolated in 1947 from cultures of a filamentous fungus which was thought to be *Stereum hirsutum*.<sup>6</sup> However, subsequent attempts to produce hirsutic acids have been unsuccessful until the present study in which the terpenoid nature of these metabolites has been proved by the efficient incorporation of  $[2-^{14}\text{C}]$ -mevalonic acid (Table 1).

TABLE 1. INCORPORATION OF  $(\pm)$ - $[2-^{14}\text{C}]$ -MEVALONIC ACID INTO HIRSUTIC ACID *C* AND COMPLICATIC ACID

Expt. No.	$[2-^{14}\text{C}]$ -MVA fed (dpm)	Hirsutic acid <i>C</i>			Complicatic acid		
		Wt. isolated (mg)	Sp. act.‡ (dpm/mg)	Incorporation§ (%)	Wt. isolated (mg)	Sp. act (dpm/mg)	Incorporation§ (%)
1*	$6.12 \times 10^6$	100.4	803.6	2.64	60.6	200	0.40
2†	$4.28 \times 10^7$	193	1339	1.26	0.0	—	—

\*  $1 \times 100$  ml culture used; harvested on day 16

†  $3 \times 100$  ml cultures used; harvested on day 7.

‡ Sequentially crystallized to constant activity ( $\pm 5\%$ ).

§ Allowing for the utilization of only the (+) enantiomer of  $(\pm)$   $[2-^{14}\text{C}]$ -MVA.

Although there is no direct evidence, it is possible that complicatic acid is identical to hirsutic acid *N* (an uncharacterized antibiotic substance which was shown to be formed from hirsutic acid *C* *in vivo*<sup>6</sup>) and ramealin (a metabolite, also uncharacterized, of *Stereum complicatum* (Fr.) Fr. (= *Stereum rameale* Schw.)).<sup>2,7</sup> In support of this we have shown that  $[^{14}\text{C}]$ -hirsutic acid *C* (biosynthesized from  $[2-^{14}\text{C}]$ -MVA) is efficiently transformed *in vivo* into II (Table 2). Furthermore, when washed mycelium of *Stereum complicatum*, harvested

<sup>2</sup> MANTLE, P. G. and MELLOWS, G. (1973) *Trans. Brit. Mycol. Soc.* in press.

<sup>3</sup> COMER, F. W., MCCAPRA, F., QURESHI, I. H. and SCOTT, A. I. (1967) *Tetrahedron* **23**, 4761.

<sup>4</sup> COMER, F. W. and TROTTER, J. (1966) *J. Chem. Soc. B*, 11.

<sup>5</sup> SCOTT, A. I. (1964) *Interpretation of the Ultraviolet Spectra of Natural Products*, Pergamon, Oxford.

<sup>6</sup> HEATLEY, N. G., JENNINGS, M. A. and FLOREY, H. W. (1947) *Br. J. Exp. Path.* **28**, 35.

<sup>7</sup> FLOREY, H. W., CHAIN, E. B., HEATLEY, N. G., JENNINGS, M. A., SAUNDERS, A. G., ABRAHAM, E. P. and FLOREY, M. E. (1949) *Antibiotics* Vol I, p. 366, Oxford University Press, Oxford.

at the time when II begins to appear in the culture fluid (*ca.* 10 days' growth), was incubated with an aqueous solution of hirsutic acid *C* at 24° during 14 hr the latter was completely converted to II. These observations are in conflict with Lansbury's assumption<sup>8</sup> that hirsutic acid *N* is identical with isohirsutic acid *C* (IV). Since hirsutic acid *N* was shown to be antimicrobial when bioassayed against *Staphylococcus aureus*<sup>6</sup> we have synthesized IV from I(R=H) and examined its antimicrobial activity. I(R=H) was reduced with LiBH<sub>4</sub> in THF to give dihydroisohirsutic acid *C*(III), m.p. 176–179°, oxidation of which with MnO<sub>2</sub> in CHCl<sub>3</sub> afforded IV as an oil. Isohirsutic acid *C* showed approximately equivalent antimicrobial activity to complicatic acid,<sup>2</sup> whereas III and I (R=H) were inactive. Hence, this parameter cannot assist in determining whether hirsutic acid *N* is identical with II or IV.

TABLE 2. INCORPORATION OF [<sup>14</sup>C] LABELLED HIRSUTIC ACID *C* INTO COMPLICATIC ACID

Expt.	[ <sup>14</sup> C] Hirsutic acid <i>C</i> fed*		Complicated acid isolated (mg)	Sp. act. of hirsutic acid <i>C</i> ‡ (dpm/mg)	Incorporation (%)
	Wt. (mg)	Sp. act. (dpm/mg)			
1†	10.2	1317	60.2	46	20.5
2†	10.2	1317	65.1	41	20.2

\* The [<sup>14</sup>C]-hirsutic acid *C* (biosynthesized from (±)-[2-<sup>14</sup>C]-MVA) was fed as an aq. soln. to one production flask (100 ml) immediately after inoculation.

† The flasks were harvested on day 14.

‡ The complicatic acid isolated was reduced (NaBH<sub>4</sub> in EtOH) to hirsutic acid *C* which was crystallized to constant activity.

We are currently isolating other related metabolites from *Stereum complicatum* and to avoid further confusion in the literature over trivial names we propose that the hypothetical parent hydrocarbon *V* be named hirsutane, numbered as shown. Thus metabolites *A* (hirsutic acid *C*) and *B* (complicatic acid) would be 5β-hydroxy-6β,7β-oxido hirsut-4(15)-en-12-oic acid and 6β,7β-oxido-5-oxohirsut-4(15)en-12-oic acid respectively. The coriolsins<sup>9</sup> would also be systematically named from this skeleton. Thus, coriolin(VI),<sup>9a</sup> the parent metabolite of this group, would be 1α,8β-dihydroxy-4β, 15:6β,7β-dioxido-5-oxo-hirsutane.

## EXPERIMENTAL

NMR spectra were recorded in CDCl<sub>3</sub> on a Varian HA-100 spectrometer using TMS as internal standard. Mass spectra were taken on an AEI MS9 spectrometer. M.ps were determined on a Kofler block and are uncorrected. Merck Kieselgel GF<sub>254</sub> nach Stahl was used for TLC and PLC. Radiocounting was carried out on a Beckman LS-200B liquid scintillation counter, in 10 ml scintillant (containing butyl PBD (6 g) and naphthalene (50 g) in toluene (11)) and ethyl cellosolve (3 ml).

**Production and isolation of I and II.** The fermentation process for the large scale (up to 300 l.) production of I and II and the extraction and purification of the metabolites, have been described elsewhere.<sup>2</sup>

**Biosynthesis experiments.** Mycelium from 6- to 10-day-old malt agar slants was used to inoculate seed flasks each containing Medium S<sup>2</sup> (100 ml). After 6–8 days growth in shaken culture, the excess supernatant

<sup>8</sup> LANSBURY, P. T., WANG, N. Y. and RHODES, J. E. (1972) *Tetrahedron Letters* 2053; LANSBURY, P. T. (1972) *Acc. Chem. Res.* **5**, 311.

<sup>9</sup> (a) TAKAHASHI, S., NAGANAWA, H., IINUMA, T., TAKITA, T., MAEDA, K. and UMEZAWA, H. (1971) *Tetrahedron Letters* 1955; (b) TAKAHASHI, S., IINUMA, H., TAKIDA, T., MAEDA, K. and UMEZAWA, H. (1969) *ibid.* 4663; (c) (1970) *ibid.* 1637.

fluid was decanted off and the mycelium blended for 1 min (Omnimix homogenizer). The total homogenate from one seed flask was used to inoculate two production flasks each containing Medium P<sup>2</sup> (100 ml). Aq. solns. of radioactive substrates were sterilized by filtration through a Sartorius membrane filter (2  $\mu$ ) before being added to the relevant number of production flasks, immediately after inoculation. The flasks were shaken at 24° for the period indicated (Tables 1 and 2). At the end of the experiment the mycelium was separated by filtration through muslin and washed with dist. H<sub>2</sub>O. The combined culture fluid and washings was extracted with CHCl<sub>3</sub> at pH 8 and the CHCl<sub>3</sub> extract discarded. The aq. layer was extracted at pH 3 with CHCl<sub>3</sub> and the latter washed with dist. H<sub>2</sub>O, dried and concentrated *in vacuo*. The acid extract was eluted on PLC with CHCl<sub>3</sub>-isoPrOH (9:1). Band *R<sub>f</sub>* 0.5-0.6, UV absorbing, afforded II and band *R<sub>f</sub>* 0.3-0.4 gave I (*R*=H), when stripped with CHCl<sub>3</sub>-isoPrOH (1:1).

**Metabolite A** (*Hirsutic acid C*, (*I,R*=H)) m.p. 178.5-180° (needles from aq. EtOH), [ $\alpha$ ]<sub>D</sub> + 116° (c 1.2, CHCl<sub>3</sub>) (cf. *hirsutic acid C*<sup>3</sup> m.p. 180°, [ $\alpha$ ]<sub>D</sub> + 116°) (Found. C, 68.0; H 7.6. Calc. for C<sub>15</sub>H<sub>20</sub>O<sub>4</sub> c, 68.1; H, 7.6%) *p*-Bromo-phenacyl ester (*I,R* =  $\cdot$ CH<sub>2</sub>CO C<sub>6</sub>H<sub>4</sub>-*p*Br) m.p. 131-132.5° (needles from EtOH) [ $\alpha$ ]<sub>D</sub> + 99° (c 1.0, CHCl<sub>3</sub>) (cf. *p*-bromo phenacyl *hirsutate*<sup>3</sup> m.p. 129-130°, [ $\alpha$ ]<sub>D</sub> + 97°). Spectral data for metabolite *A* and its ester were in excellent agreement with lit. values for *hirsutic acid C* and its ester †.

**Metabolite B** (*Complicatic acid*). Isolated as an oil, [ $\alpha$ ]<sub>D</sub> - 79° (c 1.1, CHCl<sub>3</sub>). MS showed M<sup>+</sup> 262 1208 (C<sub>15</sub>H<sub>18</sub>O<sub>4</sub> requires: 262.1205) with major fragments at *m/e* 205, 159, 85 and 83.  $\nu_{\max}$  (CHCl<sub>3</sub>) 3600-2400 br, 1730s (CO<sub>2</sub>H), 1700s, 1640 m (C=C-C=O), 1470 m, 1410 m, 1310 m, 950 m, 915 w, 900 w cm<sup>-1</sup>.  $\lambda_{\max}$  (EtOH) 234 nm ( $\epsilon$ 4500).  $\tau$  8.86, 3 Hs;  $\tau$  8.80 1 Ht (*J* 6 Hz);  $\tau$  8.64 3 Hs,  $\tau$  8.46 1 Hm;  $\tau$  8.04, 2 Hm,  $\tau$  7.95-7.10, 4 H,  $\tau$  6.65, 1 Hs;  $\tau$  4.78, 1 Hs;  $\tau$  4.01, 1H s and  $\tau$  0.0-1.2 1 Hs.

**MnO<sub>2</sub> oxidation of metabolite A.** Metabolite *A* (100 mg) in CHCl<sub>3</sub> (2 ml) was stirred during 20 hr with MnO<sub>2</sub> (500 mg). Filtration through celite and removal of solvent *in vacuo* gave a TLC pure, oily product (89 mg) identical by TLC, MS, NMR, IR and UV with metabolite *B* (*complicatic acid*).

**NaBH<sub>4</sub> reduction of metabolite B.** To metabolite *B* (200 mg) in EtOH (15 ml) was added NaBH<sub>4</sub> (200 mg) during 30 min. After a further 1 hr, the reaction mixture was poured into H<sub>2</sub>O and extracted into CHCl<sub>3</sub> at pH 3. Removal of solvent gave a white solid (191 mg) which crystallized as needles (123 mg), m.p. 179-180°, [ $\alpha$ ]<sub>D</sub> + 116° (c 1.0, CHCl<sub>3</sub>) identical with metabolite *A* (m. m.p., IR, MS and NMR).

**LiBH<sub>4</sub> reduction of *hirsutic acid C*.** A solution of *hirsutic acid* (600 mg) in dry THF (30 ml) and LiBH<sub>4</sub> (250 mg) was heated under reflux during 2.5 hr. (extended reaction time led to reduced yields of III). The complex was decomposed with sat. NH<sub>4</sub>Cl soln and the product extracted into isobutyl methyl ketone. The product was eluted on PLC with CHCl<sub>3</sub>-IPA (9:1). Band *R<sub>f</sub>* 0.4-5.0 was stripped with IPA-CHCl<sub>3</sub> (1:1) to give dihydroisohirsutic acid, III, (330 mg) as needles m.p. 176-179° (aq. EtOH), [ $\alpha$ ]<sub>D</sub> + 84° (c 1.0, EtOH). (Found: C, 67.5; H, 8.1. C<sub>15</sub>H<sub>22</sub>O<sub>4</sub> requires: C, 67.6; H, 8.3%).  $\nu_{\max}$  (KBr) 3400s, 3600-2500 br. 1705 s, 1660 w, 1210 s, 1110 s, 910 m, 880 w and 860 w cm<sup>-1</sup>. NMR (DMSO)  $\tau$  9.05, 3 Hs,  $\tau$  8.79, 3 Hs;  $\tau$  5.82, 1 Ht (*J* 8 Hz), H<sub>c</sub>;  $\tau$  5.23, 1 H br.s (*J*<sub>wz</sub> 4.8 Hz), H<sub>b</sub>;  $\tau$  5.06, 1 H br.s (*J*<sub>wz</sub> 4 Hz), H<sub>a</sub>. *Hirsutic acid C* (237 mg) was similarly recovered from band *R<sub>f</sub>* 0.3-0.4.

**MnO<sub>2</sub> oxidation of dihydroisohirsutic acid.** A soln of III (140 mg) in CHCl<sub>3</sub> (10 ml) was stirred with MnO<sub>2</sub> (1 g) during 24 hr. After usual work up, TLC pure isohirsutic acid C (IV 133 mg) was isolated as an oil MS, M<sup>+</sup> 264.1360 (15%). Calc. for C<sub>15</sub>H<sub>20</sub>O<sub>4</sub> 264.1362 with major fragments at *m/e* 246 (15%), 222 (12%), 218 (18%), 201 (30%), 200 (20%) and 124 (83%).  $\lambda_{\max}$  (EtOH) 232 nm ( $\epsilon$ 4500).  $\nu_{\max}$  (CHCl<sub>3</sub>) 3600 m, 3580-2500 br, 1725s, 1700s, 1640m, 1475m, 1415m and 950m cm<sup>-1</sup>.

**DL-[2-<sup>14</sup>C] Mevalonic Acid feeding experiments** [2-<sup>14</sup>C] MVA 135  $\mu$ Ci/mg was fed in the amounts indicated and the results are summarized in Table 1.

**[<sup>14</sup>C]-*Hirsutic Acid C* feeding experiments** [<sup>14</sup>C] *Hirsutic acid C*, biosynthesized from [2-<sup>14</sup>C] MVA, was fed in two parallel experiments during 14 days. The *complicatic acid* isolated was purified by PLC, converted to *hirsutic acid C* by NaBH<sub>4</sub> reduction and crystallized to constant activity. The results are summarized in Table 2.

**Incubation of *hirsutic acid C* with washed mycelium.** The mycelium from one 10-day-old shake flask was thoroughly washed with dist. H<sub>2</sub>O and incubated overnight with an aq. soln of *hirsutic acid C* (30 mg in 100 ml). The CHCl<sub>3</sub> extract of the aq. fraction contained TLC pure *complicatic acid*.

**Bioassay.** This was performed using the plate assay method using *Staphylococcus aureus* NCTC 6571 as the test organism.

**Acknowledgements**—We thank Professor A. I. Scott for an authentic specimen of *hirsutic acid C* and the S.R.C. for a research studentship (to T.C.F.)

† Since this work was completed we have received an authentic sample of *hirsutic acid C*, kindly sent by Prof. A. I. Scott, which was identical (TLC, m.m.p.) with metabolite *A*.